Studies involving the encapsulation of other anti-arthritic triterpenoids (considering RA, OA, and gout) such as glycyrrhizin, ginsenosides, or boswellic acids, using diverse nanosized carriers have pointed to effective inhibition of transcriptional factors NF-κB, NLRP3 inflammasome, pro-inflammatory cytokines expression and biological markers for inflammatory arthritis, thus improving the pharmacological action and bioavailability, as well as a better-controlled release of the studied triterpenes. Here, NFKB1 is linked to rheumatoid arthritis.